1. Home
  2. VALN vs QTTB Comparison

VALN vs QTTB Comparison

Compare VALN & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valneva SE

VALN

Valneva SE

N/A

Current Price

$6.48

Market Cap

495.5M

Sector

Health Care

ML Signal

N/A

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

N/A

Current Price

$15.02

Market Cap

450.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VALN
QTTB
Founded
2012
2015
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
495.5M
450.1M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
VALN
QTTB
Price
$6.48
$15.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$15.50
$13.00
AVG Volume (30 Days)
77.9K
403.3K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
136.78
EPS
N/A
N/A
Revenue
N/A
$53,737,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$93.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.75
$1.62
52 Week High
$12.23
$23.57

Technical Indicators

Market Signals
Indicator
VALN
QTTB
Relative Strength Index (RSI) 60.79 51.96
Support Level $5.03 $14.44
Resistance Level $6.60 $16.78
Average True Range (ATR) 0.24 0.72
MACD 0.00 -0.05
Stochastic Oscillator 56.42 44.52

Price Performance

Historical Comparison
VALN
QTTB

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

Share on Social Networks: